Claudin-1 publications

Journal publications

Journal of Hepatology (2025) – Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis.

Nephron (2024) – Exploring the critical role of tight junction proteins in kidney disease pathogenesis.

Journal of Hepatology (2023) – Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.

Science Translational Medicine (2022) – A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity.

Conference abstracts

American Society of Nephrology Kidney Week (2025) – Therapeutic targeting of CLDN1 reduces glomerular crescent formation and fibrosis and preserves renal function in ANCA-associated glomerulonephritis.

American Society of Nephrology Kidney Week (2025) – Targeting of CLDN1 reduces kidney injury and macrophage infiltration in FSGS.

American Thoracic Society International Conference (2024) – Expression of exposed CLDN1 Is linked to early pathological lesions in idiopathic pulmonary fibrosis.

European Renal Association Congress (2024) – Novel therapeutic for crescentic glomerulonephritis through targeting CLDN1 in parietal epithelial cells.

American Society of Nephrology Kidney Week (2023) – Claudin-1 is a therapeutic target for crescentic glomerulonephritis.